Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy.
Thyroid. 2013 Jun;23(6):675-82. doi: 10.1089/thy.2012.0267.
NKX2-1 mutations have been described in several patients with primary congenital hypothyroidism, respiratory distress, and benign hereditary chorea, which are classical manifestations of the brain-thyroid-lung syndrome (BTLS).
The NKX2-1 gene was sequenced in the members of a Brazilian family with clinical features of BTLS, and a novel monoallelic mutation was identified in the affected patients. We introduced the mutation in an expression vector for the functional characterization by transfection experiments using both thyroidal and lung-specific promoters.
The mutation is a deletion of a cytosine at position 834 (ref. sequence NM_003317) (c.493delC) that causes a frameshift with formation of an abnormal protein from amino acid 165 and a premature stop at position 196. The last amino acid of the nuclear localization signal, the whole homeodomain, and the carboxy-terminus of NKX2-1 are all missing in the mutant protein, which has a premature stop codon at position 196 (p.Arg165Glyfs32). The p.Arg165Glyfs32 mutant does not bind DNA, and it is unable to transactivate the thyroglobulin (Tg) and the surfactant protein-C (SP-C) promoters. Interestingly, a dose-dependent dominant negative effect of the p.Arg165Glyfs*32 was demonstrated only on the Tg promoter, but not on the SP-C promoter. This effect was also noticed when the mutation was tested in presence of PAX8 or cofactors that synergize with NKX2-1 (P300 and TAZ). The functional effect was also compared with the data present in the literature and demonstrated that, so far, it is very difficult to establish a specific correlation among NKX2-1 mutations, their functional consequence, and the clinical phenotype of affected patients, thus suggesting that the detailed mechanisms of transcriptional regulation still remain unclear.
We describe a novel NKX2-1 mutation and demonstrate that haploinsufficiency may not be the only explanation for BTLS. Our results indicate that NKX2-1 activity is also finely regulated in a tissue-specific manner, and additional studies are required to better understand the complexities of genotype-phenotype correlations in the NKX2-1 deficiency syndrome.
NKX2-1 基因突变已在数名患有先天性甲状腺功能减退症、呼吸窘迫和良性遗传性舞蹈病的患者中被描述,这些都是脑-甲状腺-肺综合征(BTLS)的典型表现。
对一个具有 BTLS 临床特征的巴西家族成员进行 NKX2-1 基因测序,并在受影响的患者中发现了一个新的单等位基因突变。我们使用甲状腺和肺特异性启动子在表达载体中引入突变,通过转染实验进行功能特征分析。
该突变是 834 位胞嘧啶的缺失(参考序列 NM_003317)(c.493delC),导致从第 165 位氨基酸开始的移码,并在第 196 位形成异常蛋白和过早终止。核定位信号的最后一个氨基酸、完整的同源域和 NKX2-1 的羧基末端都在突变蛋白中缺失,该蛋白在第 196 位有一个过早的终止密码子(p.Arg165Glyfs32)。p.Arg165Glyfs32 突变体不能结合 DNA,也不能激活甲状腺球蛋白(Tg)和表面活性剂蛋白-C(SP-C)启动子。有趣的是,仅在 Tg 启动子上,而不是在 SP-C 启动子上,观察到了 p.Arg165Glyfs*32 的剂量依赖性显性负效应。当在 PAX8 或与 NKX2-1 协同作用的共因子(P300 和 TAZ)存在的情况下测试该突变时,也观察到了这种效应。还将功能效应与文献中的数据进行了比较,并表明迄今为止,很难在 NKX2-1 突变、其功能后果和受影响患者的临床表型之间建立特定的相关性,这表明转录调控的详细机制仍不清楚。
我们描述了一个新的 NKX2-1 突变,并证明杂合不足可能不是 BTLS 的唯一解释。我们的结果表明,NKX2-1 的活性也以组织特异性的方式受到精细调控,需要进一步研究以更好地理解 NKX2-1 缺乏综合征中基因型-表型相关性的复杂性。